Form 13-F position report

VERTEX PHARMACEUTICALS INC

Reported by Edgemoor Investment Advisors Inc

VRTX CUSIP 92532F100 Manager CIK 0001313792

Reported 54,831 shares, down 189 (0.3%) from the prior quarter.

Reported value 4.9%; share count -0.3% vs. the prior quarter.

Reduced
% of reported 13F value 2.01% This manager · Q3 2026
Shares 54,831 Quarter-end amount reported
Reported value $28,666,115 Fair value at quarter end
Consecutive quarters held 21 Through Q3 2026

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 9734000
2022-03-31 14393000
2022-06-30 15507000
2022-09-30 16165000
2022-12-31 16033066
2023-03-31 17600755
2023-06-30 19560565
2023-09-30 19417106
2023-12-31 22941677
2024-03-31 23631149
2024-06-30 26661964
2024-09-30 26512117
2024-12-31 22993031
2025-03-31 27535920
2025-06-30 24942261
2025-09-30 21616509
2025-12-31 24862193
2026-03-31 24745392
2026-06-30 27330505
2026-09-30 28666115

Quarterly position history

How this manager's reported quarter-end position changed over time.

20 quarters
Quarterly reported position history for VERTEX PHARMACEUTICALS INC held by Edgemoor Investment Advisors Inc.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2026 Reduced 54,831 -189 (-0.3%) 2.01% $28,666,115 2026-11-03
Q2 2026 Reduced 55,020 -395 (-0.7%) 1.86% $27,330,505 2026-08-07
Q1 2026 Added 55,415 +576 (1.1%) 1.95% $24,745,392 2026-05-13
Q4 2025 Reduced 54,839 -355 (-0.6%) 1.93% $24,862,193 2026-02-10
Q3 2025 Reduced 55,194 -830 (-1.5%) 1.67% $21,616,509 2025-11-06
Q2 2025 Reduced 56,024 -772 (-1.4%) 2.15% $24,942,261 2025-08-11
Q1 2025 Reduced 56,796 -301 (-0.5%) 2.53% $27,535,920 2025-05-05
Q4 2024 Added 57,097 +92 (0.2%) 2.03% $22,993,031 2025-02-10
Q3 2024 Added 57,005 +123 (0.2%) 2.31% $26,512,117 2024-11-12
Q2 2024 Added 56,882 +350 (0.6%) 2.48% $26,661,964 2024-08-07
Q1 2024 Added 56,532 +150 (0.3%) 2.23% $23,631,149 2024-05-09
Q4 2023 Added 56,382 +544 (1.0%) 2.4% $22,941,677 2024-02-07
Q3 2023 Added 55,838 +254 (0.5%) 2.29% $19,417,106 2023-11-09
Q2 2023 Reduced 55,584 -279 (-0.5%) 2.21% $19,560,565 2023-08-09
Q1 2023 Added 55,863 +343 (0.6%) 2.14% $17,600,755 2023-05-09
Q4 2022 Reduced 55,520 -310 (-0.6%) 2.01% $16,033,066 2023-02-07
Q3 2022 Added 55,830 +799 (1.5%) 2.15% $16,165,000 2022-11-08
Q2 2022 Reduced 55,031 -122 (-0.2%) 1.95% $15,507,000 2022-08-04
Q1 2022 Added 55,153 +10,825 (24.4%) 1.52% $14,393,000 2022-05-12
Q4 2021 Added 44,328 +9,654 (27.8%) 1.0% $9,734,000 2022-02-09
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

1896 managers reported VERTEX PHARMACEUTICALS INC for Q3 2026.

Managers reporting VERTEX PHARMACEUTICALS INC in Q3 2026.
Manager Activity Shares Change % of reported 13F Reported value Tenure
Capital World Investors Reduced 25,966,793 -148,221 1.65% $13,575,850,288 54 qtrs
BlackRock Inc Reduced 23,803,111 -306,262 0.18% $12,444,504,450 9 qtrs
Capital Research Global Investors Reduced 17,814,302 -1,676,335 1.32% $9,313,657,644 15 qtrs
VANGUARD CAPITAL MANAGEMENT LLC Added 16,595,978 +15,265 0.18% $8,676,543,258 3 qtrs
STATE STREET CORPORATION Added 12,024,456 +152,997 0.18% $6,286,505,841 54 qtrs
Invesco Ltd Added 8,280,998 +237,946 0.34% $4,329,388,595 54 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 6,081,969 +64,121 0.16% $3,165,506,588 54 qtrs
JPMorgan Chase & Co Reduced 5,691,686 -825,914 0.16% $2,997,982,781 54 qtrs
Capital International Investors Added 5,059,186 +364,042 0.55% $2,645,058,681 8 qtrs
VANGUARD PORTFOLIO MANAGEMENT LLC Added 4,944,618 +65,631 0.12% $2,585,095,737 3 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
September 30, 2026
Filed
November 03, 2026
Filing type
13F-HR
Position type
COM

Voting authority reported

Sole
54,831
Shared
0
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.